Pharmacogenomics of methotrexate and candidate genes in patients with idiopathic arthritis

This article provides a comprehensive review of genetic factors that influence the pharmacokinetics and effects of methotrexate (MTX) in the treatment of juvenile idiopathic arthritis (JIA). It focuses on key genes and polymorphisms associated with MTX metabolism and transport, as well as their impact on the efficacy and tolerability of MTX therapy. The aim of the study is to review the results of genetic studies aimed at finding markers that can influence individual differences in the pharmacokinetics of MTX; to characterize the most well-studied genes involved in the pharmacogenomics of MTX and candidate genes in patients with JIA. The article analyzes the results of genetic studies published by leading international professional communities of specialists in this field. Information was searched in the PubMed and eLibrary networks.RU, Google Scholar, ClinPGx, by keywords.

1. Pastore, S., Stocco, G., Favretto, D., De Iudicibus, S., Taddio, A., d’Adamo, P., Malusà, N., Addobbati, R., Decorti, G., Lepore, L., Ventura, A. Genetic determinants for methotrexate response in juvenile idiopathic arthritis. Front Pharmacol. 2015 Mar 23; 6:52. doi: 10.3389/fphar.2015. 00052. PMID: 25852556; PMCID: PMC4369651.

2. López-Rodríguez, R., Ferreiro-Iglesias, A., Lima, A., Bernardes, M., Pawlik, A., Paradowska-Gorycka, A., Świerkot, J., Slezak, R., Dolžan, V., González-Álvaro, I., Narváez, J., Cáliz, R., Pérez-Pampín, E., Mera-Varela, A., Vidal-Bralo, L., Acuña Ochoa, J. G., Conde, C., Gómez-Reino J. J., González, A. Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May 9;8(1):7342. doi: 10.1038/s41598-018-25634-y. PMID: 29743634; PMCID: PMC5943457.

3. Umićević Mirkov, M., Coenen, M. J. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics. 2013 Mar;14(4):425–44. doi: 10.2217/pgs. 13.22. PMID: 23438889.

4. Bobkova, A. O., Lila A. M., Karateev A. E., Guseva I. A., Samarkina E. Yu., Shabatina, M. V., Konovalova, N. V., Varlamov, D. A. The associationbetween genetic characteristics and treatment failure when switching from biologic disease-modifying antirheumatic drugs/Janus kinase inhibitors in patients with rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2025; 19(1):20–28. DOI: 10.14412/1996-7012-2025-120-28

5. Lima, A., Sousa H., Monteiro J., Azevedo R., Medeiros R., Seabra V. Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers. Pharmacogenomics. 2014;15(12):1611–35. doi: 10.2217/pgs.14.116. PMID: 25340735.

6. Cole, P. D., Kamen, B. A., Gorlick, R., Banerjee, D., Smith, A. K., Magill, E., Bertino, J. R. Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res. 2001 Jun 1;61(11): 4599–604. PMID: 11389096.

7. Valiev T. T., Semenova V. V., Ikonnikova A. Yu., Petrova A. A., Belysheva T. S., Nasedkina T. V. Rol’ farmakogeneticheskih faktorov v razvitii pobochnyh effektov metotreksata pri lechenii zlokachestvennyh opuholej. Sovremennaya Onkologiya. [The role of pharmacogenetic factors in the development of methotrexate side effects in the treatment of malignant tumors. Modern Oncology.] 2021;23(4):622– 627. DOI: 10.26442/18151434.2021.4.201127.

8. Esmaili, M. A., Kazemi, A., Faranoush, M., Mellstedt, H., Zaker, F., Safa, M., Mehrvar, N., Rezvany, M. R. Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020 Jun;23(6):800–809. doi: 10.22038/ijbms.2020.41754.9858. PMID: 32695297; PMCID: PMC7351433.

9. Mikkelsen, T. S., Thorn, C. F., Yang, J. J., Ulrich, C. M., French, D., Zaza, G., Dunnenberger, H. M., Marsh, S., McLeod, H. L., Giacomini, K., Becker, M. L., Gaedigk, R., Leeder J. S., Kager L., Relling M. V., Evans, W., Klein, T. E., Altman R. B. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011 Oct;21(10):679–86. doi: 10.1097/FPC.0b013e328343dd93. PMID: 21317831; PMCID: PMC3139712.

10. Drozdzik, M., Rudas, T., Pawlik, A. et al. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 7, 404–407 (2007). doi: 10.1038/sj.tpj.6500438

11. James, H. M., Gillis, D., Hissaria, P., Lester, S., Somogyi, A. A., Cleland, L.G., Proudman, S.M. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):562–71. Epub 2008 Mar 1. PMID: 18322994.

12. Lima, A., Bernardes, M., Sousa, H., Azevedo, R., Costa, L., Ventura, F., Seabra, V., Medeiros, R. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics. 2014 Apr;15(6):807–20. doi: 10.2217/pgs.13.244. Epub 2013 Dec 18. PMID: 24350725.

13. Samara, S. A., Irshaid, Y. M., Mustafa, K.N. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014 Sep;52(9):746-55. doi: 10.5414/CP202098. PMID: 25074866.

14. Fung, K. L., Gottesman, M. M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009 May;1794(5): 860–71. doi: 10.1016/j.bbapap.2009.02.014. Epub 2009 Mar 11. PMID: 19285158; PMCID: PMC2810319.

15. Muralidharan, N., Antony, P. T., Jain, V. K., Mariaselvam, C. M., Negi V. S. Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. Eur J Clin Pharmacol. 2015 Aug;71(8):959–65. doi: 10.1007/s00228-015-1885-0. Epub 2015 Jun 14. PMID: 26071279.

16. He, X., Sun, M., Liang, S., Li, M., Li, L., Yang, Y. Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis. Pharmacogenomics. 2019 Apr;20(5): 381–392. doi: 10.2217/pgs-2018-0172. Epub 2019 Apr 15. PMID: 30983549.

17. Jenko, B., Lusa, L., Tomsic, M., Praprotnik, S., Dolzan, V. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412–418. doi: 10.1038/tpj.2016.36. Epub 2016 May 24. PMID: 27217051.

18. Suthandiram, S., Gan, G. G., Zain, S. M., Bee, P. C., Lian, L. H., Chang, K. M., Ong, T. C., Mohamed Z. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014 Aug;15(11):1479–94. doi: 10.2217/pgs.14.97. PMID: 25303299.

19. Gin-Gin Gan, Shamsul Mohd Zain, Ping-Chong Bee, Lay-Hoong Lian, Kian-Meng Chang, Tee-Chuan Ong, Zahurin Mohamed) (Yu Cheng et al., 2021 Pediatr Blood Cancer. 2021 May;68(5): e28858. doi: 10.1002/pbc.28858. Epub 2021 Jan 26. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.

20. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., Boers, G. J., den Heijer, M., Kluijtmans L.A., van den Heuvel L. P., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–3. doi: 10.1038/ng0595-111. PMID: 7647779.

21. Van der Put, N., Gabreels, F., Stevens, E., Smeitink, J., et al. (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? The American Journal of Human Genetics, 62, 1044–1051. doi:10.1086/301825.

22. Yang, L., Hu, X., Xu, L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol. 2012 Oct;33(5):144554. doi: 10.1007/s13277-012-0395-2. Epub 2012 Apr 20. PMID: 22528943.

23. Soukup, T., Dosedel, M., Pavek, P., Nekvindova, J., Barvik, I., Bubancova, I., Bradna, P., Kubena, A. A., Carazo, A. F., Veleta, T., Vlcek, J. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. Rheumatol Int. 2015 Jul;35(7):1149–61. doi: 10.1007/s00296-015-3219-z. Epub 2015 Jan 25. PMID: 25618758.

24. Chen, Y., Zou, K., Sun, J., Yang, Y., Liu, G. Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis. Pharmacogenomics. 2018 Apr;19(6):529–538. doi: 10.2217/pgs-2017-0208. Epub 2018 Mar 28. PMID: 29589488.

25. Gaughan, D. J., Kluijtmans, L. A., Barbaux, S., McMaster, D., Young, I. S., Yarnell, J. W., Evans A, Whitehead AS. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. 2001 Aug;157(2):451-6. doi: 10.1016/s0021-9150(00)007395. PMID: 11472746.

26. Guéant-Rodriguez, R. M., Juilliére, Y., Candito, M., Adjalla, C. E., Gibelin, P., Herbeth, B., Van Obberghen, E., Gueánt, J. L. Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost. 2005 Sep;94(3):510–5. doi: 10.1160/TH05-04-0262. PMID: 16268464.

27. Wessels, J. A., Kooloos, W. M., De, Jonge R., De Vries-Bouwstra, J. K., Allaart, C. F., Linssen, A., Collee, G., De Sonnaville, P., Lindemans, J., Huizinga, T. W., Guchelaar, H. J. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006 Sep;54(9):2830–9. doi: 10.1002/art.22032. PMID: 16947783.

28. Lima, A., Bernardes, M., Azevedo, R., Seabra, V., Medeiros R. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics. 2016 Oct;17(15):1649–1674. doi: 10.2217/pgs-2016-0067. Epub 2016 Sep 27. PMID: 27676277.

29. Grk, M., Milic, V., Dolzan, V., Maksimovic, N., Damnjanovic T., Pjevic M. D., Pesic M., Novakovic I., Jekic B. Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis. Pharmacogenomics J. 2020 Dec;20(6):784–791. doi: 10.1038/s41397-020-0168-z. Epub 2020 May 24. PMID: 32448869.

30. Montesinos M. C., Desai A., Chen J. F., Yee H., Schwarzschild M. A., Fink J. S., Cronstein B. N. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol. 2002 Jun;160(6):2009–18. doi: 10.1016/S0002-9440(10)61151-0. PMID: 12057906; PMCID: PMC1850820.

31. Hider, S. L., Thomson, W., Mack, L. F., Armstrong, D. J., Shadforth, M., Bruce, I. N. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford). 2008 Aug;47(8):1156–9. doi: 10.1093/rheumatology/ken182. Epub 2008 Jun 6. PMID: 18539621; PMCID: PMC2468887.

32. Judith, A. M. Wessels 1, Wouter M Kooloos, Robert De Jonge, Jeska K De Vries-Bouwstra, Cornelia F Allaart, Annelies Linssen, Gerard Collee, Peter De Sonnaville, Jan Lindemans, Tom W J Huizinga, Henk-Jan Guchelaar (Arthritis Rheum. 2006 Sep;54(9):2830–9. doi: 10.1002/art.22032. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis).

33. Stamp, L. K., Chapman, P. T., O’Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A., Roberts RL. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics. 2010 Jun; 20(6):367-76. doi: 10.1097/FPC.0b013e3283398a71. PMID: 20386493.

34. Chen, Y., Zou, K., Sun, J., Yang, Y., Liu, G. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics. 2017 Jan;18(2):175–195. doi: 10.2217/pgs-2016-0158. Epub 2016 Dec 19. PMID: 27992285.

35. Bierau, J., Lindhout, M., Bakker, J. A. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics. 2007 Sep;8(9):1221–8. doi: 10.2217/14622416. 8.9.1221. PMID: 17924837.

36. Dorado, P. M., Peñas-Lledó E. Pharmacogenetic and pharmacogenomic treatment of rheumatoid arthritis: a review of Pharmacogenomics Knowledge Base scientific evidence. Pharmacogenomics. 2024 Jan;25(2):55–58. doi: 10.2217/pgs-2023-0230. Epub 2024 Jan 17. PMID: 38230665.

37. Umićević Mirkov, M., Coenen, M. J. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics. 2013 Mar;14(4):425-44. doi: 10.2217/pgs.13.22. PMID: 23438889.

38. Dervieux, T., Wessels, J. A., van der Straaten, T., Penrod, N., Moore, J. H., Guchelaar, H. J., Kremer, J. M. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics. 2009 Dec;19(12):935-44. doi: 10.1097/FPC.0b013e32833315d1. PMID: 19858780.

39. Lima, A., Monteiro, J., Bernardes, M., Sousa, H., Azevedo, R., Seabra, V., Medeiros, R. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. Biomed Res Int. 2014; 2014:368681. doi: 10.1155/2014/368681. Epub 2014 May 21. PMID: 24967362; PMCID: PMC4055378.

40. Lima, A., Bernardes, M., Azevedo, R., Seabra, V., Medeiros, R. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics. 2016 Oct;17(15):1649-1674. doi: 10.2217/pgs-2016-0067. Epub 2016 Sep 27. PMID: 27676277.

41. Lee, Y. C., Cui, J., Costenbader, K. H., Shadick, N. A., Weinblatt, M. E., Karlson, E. W. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford). 2009 Jun;48(6):613–7. doi: 10.1093/rheumatology/ken513. Epub 2009 Feb 4. PMID: 19193698; PMCID: PMC2681284.

42. Kooloos, W. M., Wessels, J. A., van der Straaten, T., Allaart, C. F., Huizinga, T. W., Guchelaar, H. J. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics. 2010 Feb;11(2):163–75. doi: 10.2217/pgs.09.139. PMID: 20136356.

43. Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Walsh, M., Kremer, J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004 Sep;50(9):2766–74. doi: 10.1002/art.20460. PMID: 15457444.

44. Tolusso, B., Pietrapertosa, D., Morelli A., De Santis, M., Gremese, E., Farina, G., Carniello, S. G., Del Frate M., Ferraccioli G. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics. 2006 Jul;7(5):683–95. doi: 10.2217/14622416.7.5.683. PMID: 16886894.